Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. (Q39888640)

15 September 2017

title

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. (English)

1 reference

15 September 2017

0 references

1 reference

1 reference

Christine Blasey Ford

2

object named as

Christine M Blasey

0 references

Joseph K. Belanoff

4

object named as

Joseph K Belanoff

0 references

author name string

Coleman Gross

1

1 reference

15 September 2017

Robert L Roe

3

1 reference

15 September 2017

publication date

25 March 2010

1 reference

15 September 2017

1 reference

15 September 2017

volume

18

1 reference

15 September 2017

issue

12

1 reference

15 September 2017

page(s)

2295-2300

1 reference

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Weight change with atypical antipsychotics in the treatment of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Consensus development conference on antipsychotic drugs and obesity and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Off-label use of antipsychotic medications in the department of Veterans Affairs health care system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Pharmacological management of atypical antipsychotic-induced weight gain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

A meta-analysis of the efficacy of second-generation antipsychotics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Atypical antipsychotic drugs and the risk of sudden cardiac death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Mifepristone treatment of olanzapine-induced weight gain in healthy men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effectiveness of second generation antipsychotics: a systematic review of randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Methodological issues relating to the measurement of food, energy and nutrient intake in human laboratory-based studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Mortality and causes of death in schizophrenia in Stockholm county, Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Correlates of response to Olanzapine in a North Indian Schizophrenia sample.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.51

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2010.51

1 reference

release_ajvlr7ic7zdivn5rgr2bzmude4

15 September 2017

Fatcat ID

0 references

1 reference